BriaCell Therapeutics Corp. (BCTX) Long-Term Deferred Tax (2021 - 2024)
BriaCell Therapeutics (BCTX) posted Long-Term Deferred Tax of $21.9 million for Q3 2024, up 37.45% sequentially from $16.0 million in Q3 2023, and up 37.45% YoY from $16.0 million in Q3 2023.
BriaCell Therapeutics Corp. (BCTX) Long-Term Deferred Tax (2021 - 2024) Analysis & Trends
BriaCell Therapeutics has reported Long-Term Deferred Tax for 4 years, with the latest figure at $21.9 million in Q3 2024.
- Quarterly Long-Term Deferred Tax rose 37.45% year-over-year to $21.9 million in Q3 2024, while the trailing twelve-month figure through Jul 2024 was $21.9 million (up 37.45% YoY) and the FY2024 annual result came in at $21.9 million, up 37.45% from the prior year.
- Long-Term Deferred Tax improved to $21.9 million in Q3 2024 per BCTX's latest filing, from $16.0 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $21.9 million in Q3 2024 and troughed at $8.4 million in Q3 2021.
- A 4-year average of $14.6 million and a median of $14.1 million in 2022 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2022 and 2023: Long-Term Deferred Tax soared 44.59% in 2022, then soared 31.1% in 2023.
- Over 4 years, Long-Term Deferred Tax stood at $8.4 million in 2021, then jumped by 44.59% to $12.2 million in 2022, then jumped by 31.1% to $16.0 million in 2023, then surged by 37.45% to $21.9 million in 2024.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $21.9 million, $16.0 million, and $12.2 million for Q3 2024, Q3 2023, and Q3 2022 respectively.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2024 | 21.94 Mn |
| Jul 31, 2023 | 15.97 Mn |
| Jul 31, 2022 | 12.18 Mn |
| Jul 31, 2021 | 8.42 Mn |